Skip to main content

Table 1 Best overall response for patients with AML at any time on treatment

From: Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

Best overall response, n (%)

Glasdegib + LDAC

N = 78

LDAC alone

N = 38

Achieved CR

 CR

15 (19.2)

1 (2.6)

Did not achieve CR

 CRi

4 (5.1)

1 (2.6)

 PR

5 (6.4)

0

 PRi

2 (2.6)

0

 MLFS

2 (2.6)

0

 MR

4 (5.1)

4 (10.5)

 SD

14 (17.9)

9 (23.7)

 Treatment failure

9 (11.5)

7 (18.4)

 Not evaluable

23 (29.5)

16 (42.1)

  1. AML acute myeloid leukemia, CR complete remission, CRi CR with incomplete hematologic recovery, LDAC low-dose cytarabine, MLFS morphologic leukemia-free state, MR minor response, PR partial remission, PRi PR with incomplete hematologic recovery, SD stable disease
Back to article page